TECX (Tectonic Therapeutic) Common Stock : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Tectonic Therapeutic Common Stock?

Tectonic Therapeutic's quarterly common stock stayed the same from Sep. 2024 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) and stayed the same from Dec. 2024 ($0.00 Mil) to Mar. 2025 ($0.00 Mil).

Tectonic Therapeutic's annual common stock stayed the same from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil) but then increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil).

Tectonic Therapeutic Common Stock Historical Data

The historical data trend for Tectonic Therapeutic's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tectonic Therapeutic Common Stock Chart

Tectonic Therapeutic Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Common Stock

Tectonic Therapeutic Quarterly Data
	Dec21	Dec22	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Common Stock	Get a 7-Day Free Trial					-	-	-	-	-

Tectonic Therapeutic Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Tectonic Therapeutic Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tectonic Therapeutic Inc (NAS:TECX) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

490 Arsenal Way, Suite 210, Watertown, MA, USA, 02472

Website

https://www.tectonictx.com

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.